Research & Development

Medeia’s discovery and development strategy is target or novel mechanism-of-action driven rather than disorder-driven. For example, most of our discovery research programs span a combination of focus therapeutic areas in which a common neurodegenerative pathway plays a crucial role. Therefore, most of Medeia’s discovery programs will generate therapeutic opportunities for not just one, but many different medical conditions.

Currently our R&D pipeline is focused on discovering potent and selective new chemical entities (NCEs) to treat age-related diseases. Our strength lies on the combination of world-class expertise in the pathobiology of CNS diseases and deep medicinal chemistry experience. Our aim is to deliver orally active disease-modifying molecules with secured freedom-to-operate in several disease areas.

Medeia is also dedicated to explore the potential of bone marrow-derived cells as a treatment for chronic protein accumulation diseases, such as Alzheimer’s disease. For over 30 years stem cells have been in clinical use to treat hematological malignancies such as leukemia and lymphoma. Advances in (stem) cell research have revolutionized the concept of cell therapy opening whole new avenues in therapeutic areas currently incurable. Medeia’s key personnel were among the first in the world to show that bone marrow-derived cells are recruited to the brain in response of amyloid deposition in transgenic Alzheimer mice.